Applied DNA Financials
APDN Stock | USD 0.18 0.00 0.000006% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 3.17 | 3.02 |
|
|
Investors should never underestimate Applied DNA's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Applied DNA's cash flow, debt, and profitability to make informed and accurate decisions about investing in Applied DNA Sciences.
Net Income |
|
Applied | Select Account or Indicator |
Understanding current and past Applied DNA Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Applied DNA's financial statements are interrelated, with each one affecting the others. For example, an increase in Applied DNA's assets may result in an increase in income on the income statement.
Applied DNA Stock Summary
Applied DNA competes with Biodesix, DarioHealth Corp, Exagen, Burning Rock, and Neuronetics. Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York. Applied Dna operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 78 people.Specialization | Information Technology, Technology Hardware & Equipment |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US03815U3005 |
CUSIP | 03815U201 03815U300 03815U409 03815U102 |
Location | New York; U.S.A |
Business Address | 50 Health Sciences |
Sector | Electronic Equipment, Instruments & Components |
Industry | Information Technology |
Benchmark | Dow Jones Industrial |
Website | www.adnas.com |
Phone | 631 240 8800 |
Currency | USD - US Dollar |
Applied DNA Key Financial Ratios
Return On Equity | -0.76 | ||||
Profit Margin | (2.14) % | ||||
Operating Margin | (4.20) % | ||||
Price To Sales | 2.89 X | ||||
Revenue | 3.43 M |
Applied DNA Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Retained Earnings | (284.1M) | (292.5M) | (302.4M) | (309.7M) | (278.7M) | (264.8M) | |
Accounts Payable | 1.4M | 1.7M | 1.1M | 1.2M | 1.3M | 907.3K | |
Total Liab | 3.3M | 9.4M | 8.8M | 3.8M | 4.4M | 5.0M | |
Common Stock | 7.5K | 12.9K | 13.7K | 10.3K | 9.3K | 8.8K | |
Other Current Liab | 1.6M | 1.9M | 1.2M | 627.7K | 564.9K | 1.1M | |
Total Assets | 14.4M | 22.3M | 13.7M | 12.8M | 14.7M | 7.7M | |
Net Debt | (6.6M) | (15.2M) | (5.9M) | (5.7M) | (5.1M) | (4.9M) | |
Cash | 6.6M | 15.2M | 7.2M | 6.4M | 7.4M | 7.8M | |
Total Current Assets | 11.3M | 19.9M | 8.1M | 8.0M | 9.3M | 5.2M | |
Net Receivables | 2.8M | 3.1M | 255.5K | 362.0K | 416.3K | 395.5K | |
Other Current Assets | 1.1M | 2.1M | 389.2K | 816.0K | 938.4K | 530.1K | |
Net Tangible Assets | (1.9M) | 4.8M | 11.1M | 12.9M | 14.8M | 15.6M | |
Other Assets | 172.0K | 95.1K | 95.0K | 99.0K | 89.1K | 84.6K | |
Inventory | 1.4M | 602.2K | 330.0K | 438.6K | 504.4K | 357.6K | |
Other Liab | 622.0K | 848.3K | 31.5K | 5.2M | 5.9M | 6.2M |
Applied DNA Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Interest Expense | 162.4K | 115.8K | 2.0M | 13.2M | 15.2M | 16.0M | |
Operating Income | (12.3M) | (14.0M) | (11.0M) | (14.0M) | (12.6M) | (13.3M) | |
Ebit | (12.5M) | (12.5M) | (14.0M) | (11.0M) | (9.9M) | (10.4M) | |
Ebitda | (11.7M) | (12.7M) | (9.6M) | (14.0M) | (12.6M) | (13.3M) | |
Income Before Tax | (14.3M) | (8.3M) | (10.0M) | (7.1M) | (6.4M) | (6.7M) | |
Net Income | (16.0M) | (8.4M) | (9.9M) | (7.0M) | (6.3M) | (6.6M) | |
Income Tax Expense | 1.8M | 107.9K | (75.9K) | 137.3K | 157.9K | 150.0K | |
Research Development | 3.8M | 3.9M | 3.7M | 3.6M | 4.1M | 4.3M | |
Total Revenue | 9.0M | 18.2M | 13.4M | 3.4M | 3.9M | 4.8M | |
Gross Profit | 4.9M | 5.1M | 5.5M | 1.0M | 1.2M | 1.1M | |
Cost Of Revenue | 4.1M | 13.1M | 7.8M | 2.4M | 2.8M | 4.1M | |
Minority Interest | (8.0K) | 2.2K | 75.9K | 95.8K | 110.2K | 115.7K | |
Net Interest Income | 13.7K | 7.2K | 75.3K | 176.3K | 202.7K | 212.9K |
Applied DNA Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Capital Expenditures | 2.5M | 489.6K | 78.4K | 407.9K | 469.1K | 319.3K | |
Net Income | (14.3M) | (8.3M) | (9.9M) | (7.1M) | (6.4M) | (6.7M) | |
Free Cash Flow | (15.9M) | (9.5M) | (6.3M) | (14.1M) | (12.7M) | (12.1M) | |
Other Non Cash Items | 2.0M | (5.5M) | (1.1M) | (6.8M) | (6.1M) | (5.8M) | |
Change In Cash | (1.2M) | 8.7M | (7.3M) | (720.7K) | (828.8K) | (787.4K) | |
End Period Cash Flow | 6.6M | 15.2M | 7.9M | 7.2M | 8.3M | 8.7M | |
Depreciation | 844.4K | 1.3M | 1.4M | 696.4K | 626.8K | 1.0M | |
Change To Inventory | (872.6K) | 767.7K | 272.2K | (108.6K) | (124.9K) | (131.1K) | |
Change To Netincome | 2.6M | 1.0M | 3.7M | (3.0M) | (2.7M) | (2.5M) | |
Investments | (2.5M) | (489.6K) | (1.1M) | (407.9K) | (367.1K) | (385.5K) |
Applied Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Applied DNA's current stock value. Our valuation model uses many indicators to compare Applied DNA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Applied DNA competition to find correlations between indicators driving Applied DNA's intrinsic value. More Info.Applied DNA Sciences is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At this time, Applied DNA's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Applied DNA's earnings, one of the primary drivers of an investment's value.Applied DNA Sciences Systematic Risk
Applied DNA's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Applied DNA volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Applied DNA Sciences correlated with the market. If Beta is less than 0 Applied DNA generally moves in the opposite direction as compared to the market. If Applied DNA Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Applied DNA Sciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Applied DNA is generally in the same direction as the market. If Beta > 1 Applied DNA moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Applied DNA Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Applied DNA's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Applied DNA growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Applied DNA February 1, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Applied DNA help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Applied DNA Sciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Applied DNA Sciences based on widely used predictive technical indicators. In general, we focus on analyzing Applied Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Applied DNA's daily price indicators and compare them against related drivers.
Information Ratio | (0.03) | |||
Maximum Drawdown | 60.61 | |||
Value At Risk | (13.04) | |||
Potential Upside | 17.65 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Applied DNA Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Electronic Equipment, Instruments & Components space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Applied DNA. If investors know Applied will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Applied DNA listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.82) | Revenue Per Share | Quarterly Revenue Growth (0.73) | Return On Assets | Return On Equity |
The market value of Applied DNA Sciences is measured differently than its book value, which is the value of Applied that is recorded on the company's balance sheet. Investors also form their own opinion of Applied DNA's value that differs from its market value or its book value, called intrinsic value, which is Applied DNA's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Applied DNA's market value can be influenced by many factors that don't directly affect Applied DNA's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Applied DNA's value and its price as these two are different measures arrived at by different means. Investors typically determine if Applied DNA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Applied DNA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.